The 8-K filing reveals a high-stakes financial pivot for Cartesian Therapeutics, trading operational flexibility for a substantial cash infusion. While the $150 million facility provides the necessary fuel to reach commercial milestones, it binds the company to a rigid set of financial covenants and a strict amortization schedule starting in 2029. Investors must now weigh the benefit of the immediate $50 million cash injection against the risk of a 'cash squeeze' and the potential for lender-driven dilution if the company's market valuation remains suppressed.